DDInter1295 DDInter1652
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Nimodipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nimodipine {u} (Compound) binds {v} (Gene) CACNB3
Nimodipine {u} (Compound) upregulates {v} (Gene) WIF1
Nimodipine {u} (Compound) is included by {v} (Pharmacologic Class) Calcium Channel Antagonists
Nimodipine {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Nimodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Nimodipine {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Nimodipine (Compound) resembles Nisoldipine (Compound)
Nimodipine (Compound) binds CACNB3 (Gene)
Nimodipine (Compound) upregulates WIF1 (Gene)
Nimodipine (Compound) is included by Calcium Channel Antagonists (Pharmacologic Class)
Nimodipine (Compound) causes Hyperhidrosis (Side Effect)
Nimodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Nimodipine may lead to a major life threatening interaction when taken with Clarithromycin